The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Potential changes to the amyloidosis treatment landscape
In this video, Terri Parker, MD, Yale University School of Medicine, New Haven, CT, briefly comments on the potential advancements in the treatment of amyloidosis, noting that results of upcoming and ongoing trials may lead to changes in therapeutic approaches for the frontline treatment of patients. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
Yeah, I think that’s an excellent question to ponder. I think, lots of questions remain. So when looking at the upfront therapies, there are several anticipated trials looking at the anti-fibril antibodies in addition to the backbone of daratumumab, cyclophosphamide, bortezomib, and dexamethasone. So those definitely have the potential to change therapy for upfront patients...
Yeah, I think that’s an excellent question to ponder. I think, lots of questions remain. So when looking at the upfront therapies, there are several anticipated trials looking at the anti-fibril antibodies in addition to the backbone of daratumumab, cyclophosphamide, bortezomib, and dexamethasone. So those definitely have the potential to change therapy for upfront patients. And then I think there’s still the question of whether or not we should be doing autologous stem cell transplants in our patients. And there’s a current ongoing SWOG trial, S2213, that’s looking to see whether or not patients should get six cycles of dara-CyBorD or three cycles followed by autologous stem cell transplant for those who are transplant eligible. So I think some of these trials will definitely inform how we treat and manage our upfront patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
